THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES

Lobbying Spend

—

Filings

Firms Hired

Active Period

2021–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
MAGILL ASSOCIATES, LLC	—	23

Government entities explicitly identified as targets in LDA filings

Most frequently reported lobbying issues

Issue Code	Description	Reports
Budget/Appropriations	Budget/Appropriations	23
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	23

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2471117th Congress

Consolidated Appropriations Act, 2022

2022 · second_quarter · Firm: MAGILL ASSOCIATES, LLC

Cited source text and reported amounts

H.R. 2471 - Consolidated Appropriations Act, 2022 FY 2022 appropriations for the development of a synthetic vaccine

Client expense: — · Firm income: $30,000

Matched citations: H.R. 2471

H.R. 2471117th Congress

Consolidated Appropriations Act, 2022

2022 · first_quarter · Firm: MAGILL ASSOCIATES, LLC

Cited source text and reported amounts

H.R. 2471 - Consolidated Appropriations Act, 2022 FY 2022 appropriations for the development of a synthetic vaccine

Client expense: — · Firm income: $30,000

Matched citations: H.R. 2471

H.R. 2471117th Congress

Consolidated Appropriations Act, 2022

2022 · first_quarter · Firm: MAGILL ASSOCIATES, LLC

Cited source text and reported amounts

H.R. 2471 - Consolidated Appropriations Act, 2022 FY 2022 appropriations for the development of a synthetic vaccine

Client expense: — · Firm income: $30,000

Matched citations: H.R. 2471

THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES — Lobbying Disclosure | Poliscope